Compare Cytokinetics Inc (CYTK) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Alliant Energy Corporation — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Alliant Energy Corporation trades at $65.85 (market cap $16.99B). The key difference: Alliant Energy Corporation is the larger of the two by market cap, and Alliant Energy Corporation pays a 3.27% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Alliant Energy Corporation for 64 Days on average.
| CYTK | LNT | |
|---|---|---|
Market Cap | $8.62B | $16.99B |
Volume | 2,594,626 | 2,488,387 |
Sector | Health | Utilities |
52-Week High | $87.26 | $78.03 |
52-Week Low | $54.76 | $63.21 |
Typical Hold Time | 19 Days | 64 Days |
Enterprise Value | $8.72B | $29.08B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
LNT trades at $65.50, up 0.44% today, with a bullish technical signal and support near $65. The company reported Q2 2026 EPS of $0.65, beating expectations, and maintains a strong net income margin of 18.45%. Recent news highlights a $1.4B partnership and institutional buying, while a $13.4B capital expenditure plan supports long-term growth.
Outlook is positive with a consensus price target of $77, implying 17.6% upside, driven by steady utility demand and data center growth. Risks include rising debt levels and cost pressures. Analysts are bullish with 52% buy ratings, but investors should monitor execution of the capex plan and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
